For the year ended 2025-12-31, Nektar Therapeutics reported revenue of $55.23M. Revenue fell 43.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $54.59M.
Key ratios (year ended 2025-12-31)
-182.6%
Return on year-end equity
-43.9%
Revenue growth (YoY)
Annual financials
Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.
The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.
Stock splits: 1-for-15, first reflected in a filing dated 2025-08-08. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.